Rheumatology NewsTreatment with Tildrakizumab Effective for Scalp Psoriasis in Phase 3b StudyJanuary 14, 2025Psoriatic Arthritis
Rheumatology NewsNew Ideas on PsA Pathogenesis May Drive New TreatmentsJanuary 8, 2025Psoriatic Arthritis
Rheumatology NewsCardiac Risks of Newer Psoriasis Biologics vs. TNF Inhibitors ComparedJanuary 7, 2025Psoriatic Arthritis
Rheumatology NewsWhy Sex and Gender Are Important Biomarkers in PsAJanuary 3, 2025Psoriatic Arthritis
Rheumatology NewsCombined Clinics, Personalized Medicine for Psoriatic Disease Face BarriersJanuary 2, 2025Psoriatic Arthritis
Rheumatology NewsFDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024Psoriatic Arthritis
Rheumatology NewsAdalimumab for Psoriasis: Study Compares Biosimilars Vs. OriginatorDecember 2, 2024Psoriatic Arthritis
Commentary: Predicting PsA Progression, Managing Comorbidities, and Evaluating New Therapies, December 2024December 2, 2024Psoriatic Arthritis
Guselkumab Lowers Serum Biomarker Levels and Improves Disease Activity in Biologic-Naive PsA PatientsNovember 22, 2024Psoriatic Arthritis
Real-World Study Shows Severity of Psoriasis Linked to Enthesitis in PsANovember 22, 2024Psoriatic Arthritis
Identifying Predictors of Psoriatic Arthritis Progression in Patients with Arthralgia November 22, 2024Psoriatic Arthritis
